| MDWD |
MediWound Ltd. |
72%
|
s, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. Changes in t… |
| MDWD |
MediWound Ltd. |
72%
|
Reciprocal relationship from MDWD graph: Reciprocal relationship from PRFX graph: Reciprocal relationship from MDWD graph: Reciprocal relationship from PRFX graph: s, liabilities and expenses, as wel… |
| RGNT |
Regentis Biomaterials Ltd. |
72%
|
s, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. Changes in t… |
| RGNT |
Regentis Biomaterials Ltd. |
72%
|
Reciprocal relationship from RGNT graph: Reciprocal relationship from PRFX graph: s, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we co… |
| BLADE-RANGER-LTD |
BLADE-RANGER-LTD |
62%
|
omania—one of the country’s largest operational solar projects. Following the successful completion of the pilot, the we expect to expand DeepSolar’s footprint across Econergy’s portfolio, applying t… |
| BLADERANGER-LTD |
BLADERANGER-LTD |
62%
|
NOTE 13:- SUBSEQUENT EVENTS 1. On January 7, 2026, the Company held its Annual General Meeting of Shareholders, at which the shareholders approved the change of the Company’s name from PainReform Ltd… |
| COLLPLANT-LTD |
COLLPLANT-LTD |
62%
|
s, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. Changes in t… |
| ECONERGY-RENEWABLE-ENERGY-LTD |
ECONERGY-RENEWABLE-ENERGY-LTD |
62%
|
esidential market, its mobile app, MyDeepSolar, empowers homeowners to optimize their solar investments, detect inefficiencies, and reduce energy costs. The DeepSolar technology technology can cut op… |
| INCORPORATION-LAYERBIO-INC |
INCORPORATION-LAYERBIO-INC |
62%
|
ng generated limited revenue to date. To achieve commercial success for our DeepSolar solution or any future developed solution, we will need to establish a sales and marketing infrastructure or to o… |
| INTECPHARMA-LTD |
INTECPHARMA-LTD |
62%
|
s, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. Changes in t… |
| MERCK-SERONO-GROUP |
MERCK-SERONO-GROUP |
62%
|
s, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. Changes in t… |
| PAINREFORM-LTD |
PAINREFORM-LTD |
62%
|
NOTE 13:- SUBSEQUENT EVENTS 1. On January 7, 2026, the Company held its Annual General Meeting of Shareholders, at which the shareholders approved the change of the Company’s name from PainReform Ltd… |
| PHARMACEUTICS-INTERNATIONAL-INC |
PHARMACEUTICS-INTERNATIONAL-INC |
62%
|
erate no revenues from sales of any products, and we may never be able to develop a marketable product.. Our product candidates will require additional clinical development, evaluation of clinical an… |
| PRF-TECHNOLOGIES-LTD |
PRF-TECHNOLOGIES-LTD |
62%
|
a biotech company recently acquired by AbCellera on September 13, 2021, as an independent director at Sixth Element Capital, a UK-based oncology focused venture capital fund and SFH, a Maine-based nu… |
| SHAREHOLDERS-BLADERANGER-LTD |
SHAREHOLDERS-BLADERANGER-LTD |
62%
|
a biotech company recently acquired by AbCellera on September 13, 2021, as an independent director at Sixth Element Capital, a UK-based oncology focused venture capital fund and SFH, a Maine-based nu… |
